Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAPPHIRE: sitravatinib + nivolumab versus docetaxel in previously treated advanced non-squamous NSCLC
NL-OMON58689Phase 3Completed
- Sponsor
- Mirati Therapeutics
- Start
- Apr 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Non-small cell lung cancer (NS-NSCLC) comparing Sitravatinib + nivolumab with Docetaxel (2 arms). Primary endpoint: Overall Survival. Started Apr 2021; status: completed.
02
Drugs
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on NL-OMON58689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58689.